STELARA

STELARA

Displaying 10 out of 2 results

  1. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75

    Prescription drugs boost drives J&J forecasts higher, shares rise

    Johnson & Johnson on Tuesday posted a 22.9per cent rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
  2. FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California

    Pharmaceuticals drive J&J to better-than-expected quarterly profit

    Johnson & Johnson reported first-quarter revenue above analysts' estimates on Tuesday, driven partly by demand for its Stelara treatment for ...